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Abstract
Introduction: Writer’s cramp is a specific focal hand dystonia causing abnormal posturing and tremor in the upper limb. The most popular medical intervention,
botulinum neurotoxin type A (BoNT-A) therapy, is variably effective for 50–70% of patients. BoNT-A non-responders undergo ineffective treatment and may
experience significant side effects. Various assessments have been used to determine response prediction to BoNT-A, but not in the same population of patients.
Methods: A comprehensive assessment was employed to measure various symptom aspects. Clinical scales, full upper-limb kinematic measures, self-report, and
task performance measures were assessed for nine writer’s cramp patients at baseline. Patients received two BoNT-A injections then were classified as responders or
non-responders based on a quantified self-report measure. Baseline scores were compared between groups, across all measures, to determine which scores predicted
a positive BoNT-A response.
Results: Five of nine patients were responders. No kinematic measures were predictably different between groups. Analyses revealed three features that predicted
a favorable response and separated the two groups: higher than average cramp severity and cramp frequency, and below average cramp latency.
Discussion: Non-kinematic measures appear to be superior in making such predictions. Specifically, measures of cramp severity, frequency, and latency during
performance of a specific set of writing and drawing tasks were predictive factors. Since kinematic was not used to determine the injection pattern and the injections
were visually guided, it may still be possible to use individual patient kinematics for better outcomes.
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Introduction
Writer’s cramp is a task-specific form of focal hand dystonia in
which patients experience abnormal posturing and movement in the
upper limb while performing repetitive or fine motor movements,
specifically writing or drawing tasks.1 Symptoms often include a
combination of joint posturing, excessive pen grip force, and writing
tremor.2 These symptoms cause pain and discomfort in the upper
limb, further inhibiting task performance. The impairments that
writer’s cramp patients experience often intrude on their abilities to
complete professional work,3 a factor that may relate to the higher
incidence of depression and anxiety in this population.4 Therefore,
effective treatment is essential to improve quality of life and to allow
patients to re-enter the work force.
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The most popular medical intervention for treatment of writer’s
cramp is botulinum neurotoxin type A (BoNT-A) injection therapy.5
Visual assessment of posturing of the upper limb is used to guide the
injector to select appropriate muscles for injection. By temporarily
weakening the injected muscles, BoNT-A reduces local muscle activity
and directly alleviates symptoms.6 As with most treatments, however,
BoNT-A therapy is only effective for a certain percentage of the
patient population. A review by Dashtipour and Pender7 revealed that
approximately 50–70% of patients with writer’s cramp have variable
benefit from this treatment. The remaining injected patients showed
no efficacy but had the potential for substantial arm and hand
weakness that may last from weeks to months.8,9 Additionally, injec-
tions may cost patients up to 600 dollars per treatment for uninsured
therapy.10 As it regularly takes several 3-month injection cycles to
determine the efficacy of treatment or lack thereof,11 patients may
spend thousands of dollars and endure more than a year of side-effects
before being identified as a non-responder.
Unfortunately, there is currently no pre-injection method of identi-
fying patients that may respond to BoNT-A therapy. Although
Djebbari et al.12 identified some independent motor characterizations
that predicted BoNT-A response, they were unable to create a
comprehensive response profile. The issue underlying this prediction
attempt and the varied efficacy measures reported in the literature7
may be a lack of application of multiple measurements within the same
patient population. In the field of writer’s cramp research, there are
four main methods of assessing symptoms: clinical assessment, self-
reports, performance assessments, and kinematic assessments, each
with inherent limitations. Clinical assessments such as the Writer’s
Cramp Rating Scale (WCRS) are confined by a lack of consensus of
which scale offers the most accurate results. In fact, it has been shown
that these clinical scales each measure different aspects of motor
impairment.13 These scales are also confined by a lack of sensitivity.
For example, only one of the 10 items on the commonly used Unified
Dystonia Rating Scale (UDRS) pertains to hand dystonia. Kinematic
measurement offers an objective method of assessing movement, but
studies of biomechanical analyses to date have generally ignored
the multi-segmental nature of the disorder,14 focusing on specific
joint angles or applied forces.15,16 Despite the limitations of these
assessments, there remains a tendency in the literature to employ only
one scale from multiple categories,12,17 or apply only one type of
assessment.15,18–20 This lack of comprehensive measurement, which
has inhibited the development of a BoNT-A response profile for
writer’s cramp, may be overcome by implementing various measures
from all assessment categories. Therefore, the aim of the present study
is to utilize a comprehensive measurement paradigm, implemented at
baseline, to create predictive profiles of BoNT-A responders and non-
responders. The creation of such a response profile would allow
injectors to use pre-treatment assessments to predict post-treatment
improvement in writer’s cramp symptoms after BoNT-A is injected
into affected muscles based on the clinician’s best visual judgment of
the posturing of the limb.
Methods
Participants
Nine patients (three females, M5 60.2 years, SD5 7.1 years, range
51–70 years; see Table 1) diagnosed with writer’s cramp were recruited
from the London Movement Disorders Clinic at University Hospital,
London, Canada. All participants were afflicted in their dominant
hand; seven participants were right-hand dominant. Symptom dura-
tion ranged from 3 to 40 years (M 5 12.3 years, SD 5 11.2 years).
All participants were toxin naı¨ve at the start of the study. The study
was approved by the local Health Sciences Research Ethics Board
and all participants gave written informed consent. None of the
participants were receiving any other form of treatment or therapy for
their writer’s cramp symptoms 6 months before enrollment in the
study.
Procedure
Study timeline. Participants attended for a total of five visits over the
course of 32 weeks. Visits occurred at weeks 0 (visit 1), 6 (visit 2),
16 (visit 3), 22 (visit 4), and 32 (visit 5). Seven participants completed
all five visits, and two withdrew after completing the first three visits
(see Table 1, Adverse Events). Injections were given at visits 1 and 3, at
the end of the session. The two participants who withdrew from the
study after visit 3 did not receive injections at the end of that visit. The
current standard of care requires a minimum of 3 months between
consecutive BoNT-A injections; 21 an extra month washout period was
added between injections to minimize excess arm weakness. Each
visit lasted approximately 2 hours. This study is part of a larger
investigation, and therefore not all collected data are reported.
Clinical assessment. At the beginning of each visit, three clinical
scales were administered: the UDRS, the Dystonia Movement and
Disability Scale (DMDS) and the WCRS. All scales were adminis-
tered by a movement disorders neurologist (MDN) or trained research
personnel.
Kinematic sensors and assessment. Following clinical assessment,
kinematic sensors were attached and writing/drawing tasks were
completed. Four types of kinematic sensors were used to collect
biomechanical information. One force sensor placed beneath the
writing surface was used to measure the force applied down onto the
page by the participant during writing (Multi-Axis Force Sensor –
Gamma Transducer: ATI Industrial Automation Inc.). Two identical
finger pressure sensors were placed underneath thin rubber pads on
the pen. One pressure sensor was held beneath the thumb, the other
held beneath the index finger (DTS A201 FlexiForce Sensor; TekScan
Inc.). The pressure sensors were used to measure the grip force
employed during the tasks. Three electrogoniometers were placed
across the back of the wrist (Twin Axis SG150 Goniometer; Biometrics
Ltd.), the outside of the elbow (Twin Axis SG150 Goniometer;
Biometrics Ltd.) and along the top of the shoulder (Twin Axis SG150
Goniometer; Biometrics Ltd.), respectively, to measure joint angles.
Finally, one torsiometer was placed across the forearm to measure
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forearm rotation during the tasks (Single Axis Q150 Torsiometer;
Biometrics Ltd.). The kinematic sensors were attached to the affected
arm using 3M hypoallergenic micropore paper tape. All kinematic
sensors were connected to an electronic transmitter (TeleMyo2 2400T
G2 Transmitter; Noraxon Inc.) that wirelessly relayed all biomecha-
nical measurements to a laptop computer, via a receiver system
(TeleMyo2 2400R G2 Mini Receiver; Noraxon Inc.). An associated
software package (MyoResearch XP Master; Noraxon Inc.) was used
to digitally record the three-dimensional kinematic measurements in
real time during task completion.
Experimental tasks. After sensor attachment, participants com-
pleted a set of simple writing and drawing tasks. Participants were
seated on a height-adjustable chair in front of a standard desk. All tasks
were completed on printed sheets fixed on the pressure-sensitive
writing surface. Participants performed a set of 16 tasks, summarized
and listed in order in Table 2. Tasks were chosen to provide the
sensors with the most comprehensive information possible, allowing for
accurate characterization of motor abnormalities. Hovering the pen
above a fixed point on the paper provided a baseline for cramping
occurring in the absence of writing. Writing of a standard sentence was
chosen to induce cramping most representative of the original
symptom. All other tasks are standardized drawing tasks used to
break down movements made during writing into simpler components.
Kinematic assessment of these components allowed for collection of
detailed information about individual motor abnormalities. Spiral
drawing effectively localizes wrist and hand movements while mini-
mizing elbow and shoulder involvement. Similarly, connecting
two dots with a straight line isolates movement to the elbow joint.
The more complex sinusoid tracing tasks provide information
about full arm motions, as they tend to recruit full upper-limb joint
involvement.
Non-kinematic assessment. During task completion, a timer was
run continuously. Start and end times for each task were recorded.
While the participants completed each task, they were asked to state
when their cramping sensations began; this time was also recorded.
Owing to differences in individual symptomatology, ‘‘cramping’’ was
defined as ‘‘the sensation you experience that interferes with your
ability to write normally.’’ After each individual task, participants were
asked to rate the level of cramp intensity on a numerical scale from
0 (no cramp) to 4 (most severe cramping: maximal pain/discomfort).
At the end of each visit, writing quality (task performance) was assessed
for each task on a scale from 0 (normal writing quality) to 3 (severely
abnormal writing quality to completely illegible or unable to complete
task). The task performance scale was adapted from the Fahn–Tolosa–
Marin Tremor Rating Scale Section C, which is used to assess similar
writing and drawing tasks to those used in the present study.
BoNT-A injections. At the end of visits 1 and 3, participants
received injections with BoNT-A (BotoxH; Allergan Inc.: Irvine, CA;
50 units per vial). Based on the visual clinical assessment during the
writing task performed that day and prior clinical experience, the
MDN determined which muscles to inject and the toxin dose. BoNT-A
was then reconstituted (1:1 saline dilution) and injected locally into the
affected muscles by the MDN under electromyographic guidance
(Dantec Clavis2 and Bo-jectH Needle Electrodes; Natus Medical Inc.).
As per clinical standards, muscle selection and dosing were adjusted as
























01 M 52 R 3 N/A 100 4 135 4
03 M 70 R 11 * 50 4 N/A N/A
07 F 55 R 2 N/A 40 4 40 4
15 M 58 R 45 N/A 50 4 70 4
18 M 70 R 15 N/A 40 4 50 4
24 M 64 L 3 N/A 50 4 50 4
29 M 55 L 7 * 60 2 N/A N/A
32 F 55 R 7 N/A 60 6 50 6
50 F 60 R 3 N/A 90 7 135 7
*Severe weakness reported at visit 2, after first injection; patient still reporting debilitating weakness at visit 3, resulting in withdrawal from study.
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necessary for the second injection. Adjustments were based upon self-
reports of injection efficacy by the patient, reported side effects, and
clinical experience of the MDN.
Statistical analysis
All statistical analyses were performed using SPSS software, version
20.0 (SPSS Inc., Chicago, IL). Missing data are a common part of
clinical data collection.22 This study design contains two visits during
peak injection efficacy (visits 2 and 4) and three visits in which little to
no drug effects are present21 (visits 1, 3, and 5). Therefore, missing data
were replaced with data from a compatible visit. These compatible
data were used for all statistical analyses.
Response classification. Scores from the handwriting item of the
DMDS (of the Fahn–Marsden Dystonia Scales) were used to classify
patients as responders or non-responders. All item scores (0–4) on the
DMDS were multiplied by a provoking factor score (0–4) to get a total
item score from 0 to 16. The full DMDS score was not used, as other
scale items did not pertain specifically to focal hand dystonia.
Handwriting DMDS scores were compared between visits 1 (baseline)
and 4 (peak efficacy, injection 2): patients whose scores had decreased
by 50% or more between visits 1 and 4 were classified as responders;
patients whose scores had decreased by less than 50% were classified as
non-responders. Scores from visit 2 (peak efficacy, injection 1) were
used for comparison for the two patients who completed only one
injection cycle. Session notes were used to confirm whether patients
had felt they were responders or non-responders. All DMDS
classifications aligned with patients’ self-reports.
Kinematic variables. A computer software program (Matlab
R2014b: MathWorks Inc.) was used to analyze the data recorded by
the kinematic sensors during testing. Nine kinematic measures were
extracted for each of the 16 experimental tasks completed during visit 1:
thumb force (N), index force (N), hand force (N), wrist flexion–extension
( ˚ ), wrist ulnar–radial deviation ( ˚ ), forearm pronation–supination ( ˚ ),
elbow flexion–extension ( ˚ ), shoulder flexion–extension ( ˚ ), and shoulder
abduction–adduction ( ˚ ). All angular measurements were recorded in
degrees with negative numbers representing the following movement
directions: wrist/elbow/shoulder extension, wrist radial deviation, wrist
supination, and shoulder adduction. The values for each kinematic
measure were averaged across all writing and drawing tasks, giving nine
kinematic scores for each participant. The visit 1 kinematic scores for
the responder and non-responder groups were compared using separate
Mann–Whitney U tests. Any kinematic score found to be significantly
different for responders versus non-responders indicated a discrete
biomechanical marker that could be used to predict whether or not a
patient would experience improvement in his or her writer’s cramp
symptoms following BoNT-A injection therapy.
Table 2. Task Descriptions. Tasks were completed in order from 1 to 16.
Task No. Task Description
1 Hovering pen over fixed dot for 30 seconds
2 Spiral drawing (1): large, counterclockwise
3 Spiral drawing (2): small, counterclockwise
4 Spiral drawing (3): large, clockwise
5 Spiral drawing (4): small, clockwise
6 Writing standard sentence: ‘‘Today is a bright and sunny day’’
7 Connect two dots: left to right
8 Connect two dots: right to left
9 Sinusoid tracing (1): low frequency, high amplitude, left to right
10 Sinusoid tracing (2): high frequency, high amplitude, left to right
11 Sinusoid tracing (3): low frequency, low amplitude, left to right
12 Sinusoid tracing (4): high frequency, low amplitude, left to right
13 Sinusoid tracing (5): low frequency, high amplitude, right to left
14 Sinusoid tracing (6): high frequency, high amplitude, right to left
15 Sinusoid tracing (7): low frequency, low amplitude, right to left
16 Sinusoid tracing (8): high frequency, low amplitude, right to left
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Clinical and non-kinematic variables. UDRS score (units) and
WCRS score (units) refer to the total scale scores. Cramp frequency
(units) was calculated by dividing the number of tasks during which a
participant experienced cramping by the total number of tasks. Cramp
latency (seconds) was calculated by subtracting task start time (seconds)
from cramp start time (seconds); latency scores were then averaged
across all tasks. Cramp severity (units) and task performance (units)
scores were averaged across all tasks. All clinical and non-kinematic
scores were compared across responders and non-responders using
separate Mann–Whitney U tests. Any clinical or non-kinematic score
found to be significantly different for responders versus non-responders
indicated a predictive factor that could be used to predict improve-
ment in writer’s cramp symptoms following BoNT-A injection therapy.
z-Score calculation and profile creation. For measures that
showed a significant difference (or a difference trending towards
significance) between responders and non-responders, z-scores were
calculated. These z-scores were used to determine relative levels of
‘‘high’’ and ‘‘low’’ scores on the predictive measures, as no literature
basis for such average scores exists to our knowledge.
Results
BoNT-A response
Consistent with rates reported in literature, statistical analysis
revealed a 56% response rate; the following five patients exhibited
50% or greater rectification of their writer’s cramp symptoms, as
determined by a decreased in DMDS handwriting scores between
visits 1 and 4: WC-01 (67% reduction), WC-07 (100% reduction),
WC-18 (50% reduction), WC-32 (100% reduction), and WC-50 (50%
reduction). These patients were thus classified as BoNT-A responders.
The remaining four patients exhibited symptom reduction of less than
50%, or symptom worsening between visits 1 and 4: WC-03 (50%
worsening), WC-15 (0% reduction), WC-24 (33% reduction), and WC-
29 (200% worsening). These patients were therefore categorized as
BoNT-A non-responders. Patients who experienced symptom worsen-
ing reported that their increased handwriting difficulties were due to
excessive weakness. Session notes indicated that regardless of weak-
ness, these patients were not satisfied with the symptom reduction
achieved by BoNT-A therapy.
Kinematic predictors
Statistical analyses (Mann–Whitney U tests) revealed no significant
difference between groups for any of the nine recorded kinematic
measures. None of the three measured forces was found to be signi-
ficantly different between BoNT-A responders and non-responders
(see Figure 1A): thumb force (U [7]58.0, p50.624), index finger force
(U [7]59.0, p50.806), and hand force (U [7]58.0, p50.624). Thus
none of these forces were biomechanical indicators of BoNT-A therapy
response. Likewise, none of the six measured joint angles was found
to be significantly different between responders and non-responders
(see Figure 1B): wrist flexion/extension (U [7]59.0, p50.806), wrist
radial/ulnar deviation (U [7]57.0, p50.462), wrist pronation/supina-
tion (U [7]57.0, p50.462), elbow flexion/extension (U [7]5 9.0,
p50.806), shoulder flexion/extension (U [7] 5 4.0, p 5 0.142), and
shoulder abduction/adduction (U [7]57.0, p50.462). Therefore, the
measured joint angles also did not reveal any kinematic predictors.
Clinical and non-kinematic predictors
For the clinical scales, self-reports and task performance measures,
statistical analyses (Mann–Whitney U tests) revealed a significant
difference in cramp severity scores (U [7]50.0, p50.014] (Figure 2A)
and in cramp frequency scores (U [7]51.0, p 5 0.026) (Figure 2B)
between BoNT-A responders and non-responders. Both cramp
severity and frequency represent predictive factors. Although statistical
analyses revealed a non-significant difference in cramp latency scores
(U [7]54.0, p50.124) (Figure 2C) between responders and non-
responders, this assessment score was trending towards significance.
Therefore, cramp latency scores were also used as predictive factors in
Figure 1. Kinematic Results. (A) Mean (¡standard error [SE]) finger and hand forces across all tasks. (B) Mean (¡SE) joint angles across all tasks. Positive
values represent (respectively): wrist flexion, wrist radial deviation, wrist pronation, elbow flexion, shoulder flexion, shoulder adduction.
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the subsequent response profile creation. Statistical analyses revealed
no significant difference for the following clinical and non-kinematic
assessment scores: UDRS scores (U [7]57.5, p50.521) (Figure 2D),
WCRS scores (U [7]58.5, p50.706) (Figure 2E), and task performance
(U [7]57.0, p 5 0.462) (Figure 2F). Thus none of these scores was
a predictor of BoNT-A therapy response and none was used in
subsequent profile creation.
Response profile
Compared with non-responsive patients, BoNT-A responders
tended to have high cramp frequency (Figure 3A), high cramp severity
(Figure 3B), and low cramp latency (Figure 3C). Therefore, above-
average (high) scores on cramp severity and cramp frequency as well as
a below-average (low) score for cramp latency were considered
predictors of improvement in writer’s symptoms following BoNT-A
therapy. High or low scores were those above or below the following
averages, respectively: cramp severity (M51.48 units, SD50.80 units),
cramp frequency (M50.75 units, SD50.21 units), and cramp latency
(M50.42 seconds, SD50.17 seconds). z-Score results were used to
determine whether individual participants fell into each of the
predictive categories. z-Score results are represented in Figure 3.
Coincidence of these three predictive categories for each patient is
examined in Figure 4, giving a visual representation of how each
patient fits into the BoNT-A response profile. The three patients
who experienced the largest reduction in DMDS handwriting scores
(WC-01, WC-32, and WC-50; data not shown) fit into all three
Figure 2. Clinical and Non-kinematic Results. Asterisks represent a significant difference between groups. (A) Mean (¡standard error [SE]) cramp severity
scores across all visit one tasks. (B) Total (¡SE) cramp frequency score for visit one. (C) Mean (¡SE) cramp latency scores across all visit one tasks. (D) Total (¡SE)
Unified Dystonia Rating Scale score from visit one. (E) Total (¡SE) Writer’s Cramp Rating Scale score from visit one. (F) Mean (¡SE) task performance scores
across all visit one tasks.
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predictive categories. The remaining two responding patients (WC-07
and WC-18) each fit into two of the three predictive categories.
Three non-responsive patients (WC-03, WC-15, and WC-29) exhibited
no predictive response factors. The final non-responsive patient (WC-24)
exhibited low latency in the absence of any other predictive factor.
Discussion
This investigation used a comprehensive assessment paradigm to
determine which measurements were predictive of improvement in
writer’s cramp symptoms following BoNT-A injection therapy.
As predicted, the response rates from the present study matched the
literature-reported 50–70% efficacy rate,7 with 56% of participants
BoNT-A responsive.
Despite previous findings by Djebbari et al.12 that increased wrist
flexion and forearm pronation were kinematic predictive factors, the
current study found no biomechanical predictors. The discrepancy in
these results may be due to methodological differences. The present
study employed a biomechanical assessment paradigm, but Djebbari
et al.12 utilized a visual assessment paradigm. More specifically, the
lack of kinematic predictors identified in this study may be due to the
small sample size and the large individual variation in biomechanical
measurements (discussed below). Further, it is possible that a lack of
explicit analysis of finger and thumb flexion and extension precluded
kinematic predictive factors from being identified. Finally, the present
study did not employ simultaneous needle electromyography record-
ing alongside the kinematics, in an attempt to limit invasive study
procedures. Such recordings may have helped guide kinematic analysis
by identifying which muscles are the major generators of involuntary
movements. Despite these biomechanical assessment limitations, the
lack of kinematic significance may be a fortuitous finding in terms
of clinical relevance. The kinematic system used in this study is rela-
tively expensive, and the kinematic recordings take approximately
30 minutes to complete. It is therefore more realistic for an injector to
adopt a short non-kinematic assessment routine as a BoNT-A therapy
screening paradigm.
Clinical and non-kinematic results indicated that BoNT-A-responsive
patients exhibited all (or a selection of) the following response factors:
higher than average cramp severities and cramp frequencies, and
below-average cramp latencies. These three factors thus formed a
simple yet comprehensive profile of BoNT-A response for writer’s
Figure 3. z-Scores for Response Profile Measures. Light-grey bars represent responders, and dark-grey bars represent non-responders. Positive values
represent above average scores. (A) Cramp frequency (mean50.75 units). (B) Cramp severity (mean51.48 units). (C) Cramp latency (mean50.42 seconds).
Figure 4. Response Profile. Patient numbers in brackets: square brackets
indicate responders, curved brackets indicate non-responders. Three response
predictors identified in previous analyses represented: high cramp severity,
high cramp frequency, and low crap latency. Circle intersections represent
co-occurrence of response predictors in patient assessment.
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cramp patients. By matching each patient’s results to the response
profile, it was shown that any patient whose results fit into two or
more of the defined predictive categories is likely to be a responder,
with a better degree of improvement for those falling into more
predictive categories. On the other hand, patients exhibiting one or
fewer response factors are most likely non-responders. The one non-
responder who fit one predictive category had a DMDS score
reduction rate only slightly below the level required to be classified as
a responder. This may indicate that the response profile can be used
to predict degree of responsiveness to BoNT-A therapy, rather than
simply predicting binary response versus non-response categories.
Importantly, all three predictive scores were related to completion of
a set of 16 writing and drawing tasks designed specifically for this
investigation. Taken together, these results suggest the creation of a
short and inexpensive BoNT-A screening paradigm, discussed below,
which may be implemented in a clinical setting.
Being an exploratory, proof of concept clinical investigation, this
study did have limitations. The major drawbacks of this investiga-
tion were the small sample size and the lack of placebo control and
blinding. The small sample undermined statistical power23 and likely
contributed to the lack of statistically significant kinematic findings. In
addition, a larger sample size would provide more security for the
calculated response rate matching the literature reported response
rate, thus increasing generalizability of the results. It may be noted,
however, that previous studies investigating this patient population
have utilized comparably small sample sizes: Baur et al.,24 (seven
participants); Kimberley et al.,25 (12 participants); Rosenkranz et al.26
(two groups of six participants). The other major limitation was that all
injections were carried out on the basis of visual assessment. Although
visual determination of injection parameters is the clinical standard,5
the subjective nature of this practice suggests that literature reported
efficacy rates may be due to suboptimal injections by physicians.
A more objective means of determining injection parameters could
increase BoNT-A therapy efficacy, eliminating the need for predictive
analyses. Regardless, such a method does not yet exist. Clinicians will
likely continue to use visual assessment to determine injection para-
meters for the foreseeable future, necessitating a predictive profile.
Therefore, the results of the present study have important clinical
relevance. As previously discussed, for the 30–50% of patients for
whom BoNT-A therapy is ineffective,7 these treatments can unne-
cessarily cost thousands of dollars and up to a year of life-altering arm
and hand weakness. Although BoNT-A treatment professionals may
be able to minimize severity or longevity of negative physical side
effects of this treatment, the monetary limitations remain a likely
barrier for many prospective patients. Clinicians could alleviate these
issues by adopting a simple BoNT-A therapy screening paradigm,
consisting of completion of the 16 writing and drawing tasks used
in this study. Adoption of this simple paradigm by clinicians would
take only approximately 10 minutes for task completion and score
calculation, but would save patients large amounts of time, money, and
quality of life alterations.
The next step in continuing this research is to utilize a larger sample
size, in order to increase statistical power and generalizability.23,27 The
use of a larger sample size would result in generation of average
response factor scores (cramp severity, frequency, and latency) that
could be applied widely in a clinical setting. In the future, these
response factors could be analyzed using a linear regression analysis to
create a response algorithm. If predictive weights of the various scales
and scores are determined and input into the regression, this algorithm
may even have the power to predict to what degree the treatment will
be effective for a given patient. Researchers may then consider
applying this method of profile creation to other patient populations.
For example, to essential tremor patients who receive BoNT-A therapy
for tremor relief.28 Additionally, recent research has shown that
writer’s cramp patients have unique, pre-treatment kinematic sympto-
matology profiles.29 Therefore, a larger scale step for this line of
research is to examine the relationship between writer’s cramp
symptom characteristics and treatment outcome. Future researchers
may also investigate the role of mechanism of action of BoNT-A on
variability of treatment outcomes for writer’s cramp patients.
Although no biomechanical predictors of BoNT-A response were
identified in this study, kinematic assessment has much to offer the field
of writer’s cramp research. Full upper-limb kinematic measurement
remains a novel assessment tool for writer’s cramp and should
undoubtedly be investigated further. The large variability in the
kinematic recordings taken during this study imply that writer’s cramp
patients each have unique profiles of motor abnormalities. This has
implications for improving BoNT-A injection therapy by optimizing
injection parameter determination. The use of objective kinematic
sensors may allow for a more sensitive determination of which muscles
are hyperactive, leading to more effective determinations of BoNT-A
injection parameters.
In conclusion, this study implemented a novel, comprehensive
assessment paradigm to predict improvement in writer’s cramp
symptoms following BoNT-A injection therapy. The results showed
that responsive patients fit into two or more of the following predictive
categories: high cramp severity, high cramp frequency, and low cramp
latency. Although further investigation with increased sample size is
required before this profile can be clinically utilized, proof of concept
was shown for creation of a comprehensive profile that predicts BoNT-
A therapy response.
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